Cas:36980-34-4 N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-1-ethyl-3-methyl-4-(3-methylbutoxy)pyrazolo[3,4-b]pyridine-5-carboxamide manufacturer & supplier

Chemical Name:N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-1-ethyl-3-methyl-4-(3-methylbutoxy)pyrazolo[3,4-b]pyridine-5-carboxamide

CAS.NO:36980-34-4

Synonyms:Glicaramidum [INN-Latin];Glicaramide [INN];UNII-UK5SR22C8Q;Glicaramidum;Glicaramida [INN-Spanish];1-ethyl-3-methyl-4-(3-methyl-butoxy)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 4-(cyclohexylcarbamoyl-sulfamoyl)-phenethylamide;Glicaramide;Glicaramida

Molecular Formula:C₃₀H₄₂N₆O₅S

Molecular Weight:598.75700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.32g/cm3

Index of Refraction:1.634

PSA:159.67000

Exact Mass:598.29400

LogP:6.72850

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Glicaramidum [INN-Latin] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Glicaramida physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Glicaramidum [INN-Latin] Use and application,Glicaramida technical grade,usp/ep/jp grade.

Related News: FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-1-ethyl-3-methyl-4-(3-methylbutoxy)pyrazolo[3,4-b]pyridine-5-carboxamide manufacturer FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-1-ethyl-3-methyl-4-(3-methylbutoxy)pyrazolo[3,4-b]pyridine-5-carboxamide supplier The U.S. Food & Drug Administration on Friday said Johnson & Johnson (JNJ.N) must throw away millions of doses of its COVID-19 vaccine that were manufactured at a problem-plagued Baltimore factory but also cleared millions for use. N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-1-ethyl-3-methyl-4-(3-methylbutoxy)pyrazolo[3,4-b]pyridine-5-carboxamide vendor FT was defined as any difficulty paying medical bills, high financial distress, cost-related medication nonadherence, food insecurity, and/or foregone/delayed care due to cost. N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-1-ethyl-3-methyl-4-(3-methylbutoxy)pyrazolo[3,4-b]pyridine-5-carboxamide factory Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.